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Background: Carotid intima-media thickness (C-IMT) is a reliable predictor of cardiovascular events. We Investigated
the relationship between markers of glycemia and C-IMT in intermediate-risk cardiovascular patients.
Methods: This study analyzed 427 subjects, aged 35 to 74 years (mean, 60.3 ± 8.5 years), 55 % women, enrolled
into the MARK study. Including 231 subjects defined as normal glucose, 104 subjects classified as prediabetes and
92 with type 2 diabetes mellitus. Carotid ultrasound was used to measure C-IMT and the presence of plaques.
Fasting plasma glucose (mg/dl) and glycated hemoglobin (%) (HbA1c) were measured using standard enzymatic
automated methods. Postprandial glucose (mg/dl) was self-measured by patients at home 2 h after meals
(breakfast, lunch and dinner) for 1 day.
Results: The C-IMT shows a positive correlation with fasting plasma glucose, postprandial glucose and HbA1c.
Multiple linear regression analysis showed a positive association between HbA1c and C-IMT, with a 0.016 mm and
0.019 mm increase in mean and maximum C-IMT per 1 % increase in HbA1c. In addition, an association between
fasting plasma glucose and C-IMT was found with an increase of 0.004 and 0.005 mm in mean and maximum
C-IMT per 10 mg/dl in fasting plasma glucose. We also observed a graded association between fasting plasma
glucose, postprandial glucose and HbA1c and the presence of carotid target organ damage (TOD), with an odds
ratio of 1.013, 1.010 and 1.425, respectively.
Conclusion: The results of this study suggest that the fasting plasma glucose and HbA1c, but not postprandial
glucose, are associated with C-IMT media and maximum. The patients who present with a metabolic glucose
alteration have more risk of developing carotid TOD.
Trial registration: ClinicalTrials.gov; Identifier: NCT01428934.
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A positive relationship between the glycosylated hemoglobin
(HbA1C), fasting plasma glucose and postprandial glucose
with cardiovascular morbidity in diabetes patients has been
shown in several studies [1, 2]. In people free of diabetes,
this association is not clear, and studies suggest that there is* Correspondence: magomez@usal.es
1Primary Care Research Unit, the Alamedilla Health Center, 37003 Salamanca,
Spain
2Castilla and León Health Service–SACYL, REDIAPP. IBSAL, Salamanca, Spain
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zea higher association with HbA1c [1, 3–6] than with others
parameters. However, patients with type 2 diabetes and
those with glucose intolerance present with a carotid thick-
ness that is 0.13 and 0.04 mm wider than the carotid thick-
ness of the control subjects. These results are similar in
different ethnicities and in both sexes [7].
The association between HbA1c, fasting glucose and
postprandial glycemia with the carotid intima-media
thickness (C-IMT) is different in diabetic patients com-
pared with non-diabetic people [8]. Studies that have ana-
lyzed the relationship between HbA1c and intima-mediale is distributed under the terms of the Creative Commons Attribution 4.0
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inconclusive. Studies showed a positive association be-
tween HbA1c and 1-h post load plasma glucose and C-
IMT [2, 3]. However, the Dong-gu study [4] showed that
HbA1c level was independently associated with arterial
stiffness, but not with carotid atherosclerotic parameters,
in the overall population without diabetes. Choi et al.
[9] recently showed an association with the presence
of cholesterol fatty plaques in the coronary artery
walls but not with the C-IMT in Korean diabetic pa-
tients. However, there was a positive association in
Japanese diabetics with fatty plaques of cholesterol on
the coronary artery walls [10].
A positive association between glycemia and C-IMT in
the general population has been described in several
studies [11, 12]. The association between postprandial
glucose and the C-IMT that was analyzed by Kato et al.
[13], using the 2-h plasma glucose measurement during
an oral glucose tolerance test, was positively and inde-
pendently associated with C-IMT in Japanese subjects
with normal glucose tolerance, which is in agreement
with the results published by Andreozzi F et al. [8]. Xing
F et al. [6] found a relationship between the HbA1c and
the basal glucose level C-IMT in prediabetic patients,
but this association did not remain after an adjustment
for other cardiovascular risk factors. Tanaka et al. [14]
showed that the increase in glycemia one hour after 75 g
of glucose overload was the only parameter that was as-
sociated with C-IMT, but Hot et al. [15] did not show
that association.
Thus, the association of normoglycemic levels with sub-
clinical cardiovascular measures remains controversial and
is of particular interest, given that this association would
potentially affect a larger proportion of the population.
The association between markers of glycemia and vascu-
lar structure in patients with intermediate cardiovascular
risk has not been determined. In patients with intermedi-
ate cardiovascular risk, it is important to analyze new car-
diovascular risk factors and the association between them
for personalized risk stratification. Therefore, we investi-
gated the relationship between markers of glycemia and




This study enrolled 427 subjects, who were included at
the baseline of the MARK study and who underwent
fasting glucose, postprandial glucose and glycosylated
hemoglobin (HbA1c) tests, and also carotid ultrasonog-
raphy. The MARK study is a cross-sectional study to evalu-
ate if ankle-brachial index (ABI) measures of arterial
stiffness cardio-ankle vascular index (CAVI), postprandial
glucose, glycosylated hemoglobin, self-measured bloodpressure and presence of comorbidity are independently as-
sociated with the incidence of vascular events, and whether
they can improve the predictive capacity of the current risk
equations in the intermediate-risk population. The second
step will be a 5–10-year follow-up to evaluate cardiovascu-
lar morbidity and mortality (NCT01428934) [16].
Study population
Population aged between 35 and 74 years who have an
intermediate cardiovascular risk, defined as coronary
risk between 5 and 15 % at 10 years according to the
Framingham adapted risk equation [17], vascular mortal-
ity risk between 1 and 5 % at 10 years according to the
SCORE equation [18] or moderate risk according to the
2013 European Society of Hypertension guidelines for
the management of arterial hypertension [19]. This study
analyzed 427 subjects enrolled in MARK study. Includ-
ing 231 subjects defined as normal glucose, 104 subjects
classified as prediabetes and 92 with type 2 diabetes
mellitus. In the 335 patients without prior diagnosis of
diabetes we have adapted the cut-offs of HbA1c, fasting
plasma glucose (FPG) and postprandial glucose (PG)
according to current American Diabetes Association cri-
teria [20]. We have considered prediabetes if HbA1c be-
tween 5.7 and 6.4 or FPG between 100 and 125 mg/dL or
PG between 140 and 199 mg/dL and not diagnostic de
type 2 diabetes mellitus, and metabolism of glucose nor-
mal if HbA1c ≤5.7 or FPG ≤100 mg/dL or PG ≤140 and
not diagnostic of type 2 diabetes mellitus or prediabetes.
The exclusion criteria were terminal illness, institutiona-
lization at the appointment time or a personal history of
atherosclerotic disease. Sample selection was done using a
random sample from the population aged 35 to 74 years
(both included) who had an intermediate cardiovascular
risk. Recruitment and data collection for the study oc-
curred from July 2011 to June 2013. A sample-size calcula-
tion indicated that the 427 patients included in this study
constituted a sufficient sample for detecting a correlation
coefficient of 0.135 between fasting glucose and C-IMT in
a two sided test, with a level of significance of 95 % (alfa
risk 0.05) and a power of 80 % (beta risk 0.20). The study
was approved by an independent ethics committee in the
Salamanca health area (Spain), and all participants gave
written informed consent, according to the general recom-
mendations of the Declaration of Helsinki [21].
Measurements
A detailed description has been published elsewhere re-
garding collection of clinical data, anthropometric mea-
surements and analytical parameters [16].
Laboratory determinations
Venous blood sampling was performed between 08:00
and 09:00 after the individuals had fasted and abstained
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feinated beverages for the previous 12 h. Fasting plasma
glucose, HbA1c, serum total cholesterol and high-
density lipoprotein (HDL) cholesterol concentrations
were measured using standard enzymatic automated
methods. Blood samples were collected in the Alamedilla
Health Center and analyzed at the Salamanca Hospital,
which was approved by the Spanish Society of Clinical
Chemistry and Molecular Pathology external quality as-
surance programs. Postprandial glucose (mg/dl) was
self-measured by patients at home 2 h after meals
(breakfast, lunch and dinner) for 1 day using an Accu-
chek® glucometer (Roche Diagnostics Corporation, Spain).
Postprandial glucose was calculated as the average of the
three measurements. We considered glucose metabolism
to be impaired if the patient had diabetes or impaired fast-
ing glucose (between 100 and 126 mg/dl) or HbA1c (be-
tween 5.7 and 6.4) or postprandial glucose (between 140
and 200 mg/dl) [14].
Office blood pressure
Office blood pressure (BP) was calculated as the average
of the last two of three measurements of systolic blood
pressure (SBP) and diastolic blood pressure (DBP) made
using a validated sphygmomanometer (OMRON Model
M10-IT). Measurements were made using the partici-
pant’s dominant arm when they were in a seated position
after at least 5 min of rest, with a cuff of appropriate size
as determined by measurement of the upper-arm circum-
ference according to the European Society of Hyperten-
sion recommendations [22].
Assessment of vascular structure using carotid intima
media thickness
Two trained investigators performed the carotid ultra-
sound to assess carotid C-IMT before starting the study.
Before the study, the reliability of the recordings was
evaluated using the intra-class correlation coefficient,
which showed values of 0.97 (95 % CI: 0.94 to 0.99) for
intra-observer agreement of repeated measurements in
20 subjects, and 0.90 (95 % CI: 0.74 to 0.96) for inter-
observer agreement. According to the Bland-Altman
analysis, the mean difference for inter-observer agree-
ment (95 % limit of agreement) was 0.01 (−0.03 to 0.06).
A Sonosite Micromax ultrasound (SonoSite, EE.UU de-
vice paired with a 5–10 MHz multi-frequency high-
resolution linear transducer with Sonocal software was
used for to automatically measure the C-IMT. There
were 120 values obtained automatically, ten measure-
ments in each of the 12 projections, to optimize repro-
ducibility. The common carotid was measured after
examining a 10-mm longitudinal section at a distance of
1 cm from the bifurcation, and measurements were also
taken of the proximal wall. The lateral (90 °), anterior(45 °) and posterior (135 °) projections in the distal wall
followed an axis perpendicular to the artery to distin-
guish between two lines: one for the intima-blood inter-
face and the other for the media-adventitious interface.
A total of six measurements of the right carotid artery
and six measurements of the left carotid artery were ob-
tained, and the average values (average mean C-IMT and
average maximum C-IMT) were automatically calculated
by the software [23]. The measurements were obtained
with the subject lying down, with their head extended
and slightly turned opposite to the carotid artery that
was examined. It was considered as carotid TOD if ex-
ists a plaque or a carotid IMT >0.9 mm. Presence of a
plaque was identified by an IMT ≥1.5 mm or by a focal
increase in thickness of 0.5 mm or 50 % of the surround-
ing carotid IMT value [19].
Others measurements
Anthropometric measurements Body mass index (BMI)
was calculated as weight (kg) divided by height squared
(m2). A value of >30 kg/m2 was considered to define obesity.
Lifestyles Tobacco
Smoking history was assessed by asking questions about
the participant’s smoking status (smoker/non-smoker) and
the number of cigarettes/day for the smokers. We consid-
ered smokers to include those who currently smoke or
who have stopped smoking within the past year.
Alcohol
Alcohol consumption was assessed through a structured
questionnaire and was expressed in grams per week.
Physical activity
Leisure time physical activity (LTPA) practice was col-
lected using the Minnesota LTPA Questionnaire that
was validated for Spanish men and women [24, 25]. The
questionnaire was administered by trained interviewers
and it collected detailed information about physical activ-
ity during the preceding year, the number of times this ac-
tivity was performed and the average duration of each
activity on each occasion. Each physical activity has an in-
tensity code, based on the ratio between the metabolic
rate during PA practice and the basal metabolic rate. Con-
sumption in mean metabolic equivalents (METs) -min
was estimated over 14 days by multiplying the MET in
physical activity with the duration (in minutes) and cumu-
lative frequency in the month before the interview.
The individuals performing the different tests were
blinded to the patient’s clinical data. All assessments
were made within a period of 10 days.
Statistical analysis
Continuous variables were expressed as the mean ± stand-
ard deviation for normally-distributed continuous data, the
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distributed continuous data and as a frequency distribution
for categorical data. Statistical normality was tested using
the Kolmogorov–Smirnov test. Pearson correlation was
performed to analyze the relationship between quantitative
variables and Spearman’s correlation was used to analyze
the relationship between asymmetrically-distributed con-
tinuous data. Analysis of variance (ANOVA) was used to
determine differences in the means between more than two
categories of quantitative variables for symmetrically dis-
tributed continuous data. Comparisons between three orTable 1 Baseline demographic and clinical characteristics of patient
Global (n = 427) Dia
Age (years) 60.3 ± 8.5 59.
Gender (women) n (%) 236 (55.3) 63
Smoker n (%) 82 (21.5) 19
Alcohol drinking (gr/week) 76.6 ± 108.1 60.
METs/hour/week 3623 ± 3431 337
Body mass index (kg/m2) 28.3 ± 4.2 29.
Abdominal perimeter (cm) 97.5 ± 10.6 102
Obesity patients n (%) 128 (27.6) 38
Office SBP (mmHg) 134 ± 17 137
Office DBP (mmHg) 81 ± 11 79.
Office MBP (mmHg) 93 ± 10 93.
Office Heart rate (bpm) 70 ± 11 73.
Hypertensive patients n (%) 340 (79.6) 76
Antihypertensive Drugs n (%) 230 (53.9) 60
FPG (mg/dL) 97.9 ± 31.1 137
Average PG (mg/dL) 120.2 ± 32.4 152
HbA1c (%) 5.9 ± 1.0 7.2
Diabetics patients n (%) 92 (21.5) 92
Antidiabetic drugs n (%) 76 (17.8) 76
Total Cholesterol (mg/dl) 215.0 ± 38.93 193
LDL Cholesterol (mg/dl) 134.3 ± 34.5 113
HDL-Cholesterol (mg/dl) 55.1 ± 14.3 51.
Tryglicerides (mg/dl) 129.4 ± 92.6 149
No HDL-Cholesterol (mg/dl) 80.2 ± 13.8 79.
Dyslipidemia patients n (%) 363 (85) 66
Lipid lowering drugs n (%) 158 (37) 56
Average mean IMT (mm) 0.738 ± 0.096 0.7
Carotid plaques n (%) 75 (17.6) 28
TOD carotid n (%) 77 (18.0) 29
Average maxima IMT (mm) 0.906 ± 0.117 0.9
Values are means and standard deviations (SD) for distributed continuous data, and
METs metabolic equivalents, SBP systolic blood pressure, DBP diastolic blood pressu
glucose, HbA1c glycosylated hemoglobin, LDL low density lipoprotein, HDL high de
target organ damage
No HDL-Cholesterol mg/dl = (Total Cholesterol – HDL Cholesterol)
TOD = Plaque or carotid IMT >0.90 mmmore groups were also made using ANOVA and differ-
ences between groups were assessed using the Bonferroni
post hoc test.
We performed multiple linear regression analyses, one
for each dependent variable, with C-IMT mean and
maximum (×100) to facilitate interpretation of fasting
glucose, average postprandial glycemia and HbA1c as in-
dependent variables. We adjusted by age and gender
(Model 1), and by age, gender, heart rate, smoker, body
mass index, no HDL-cholesterol, systolic blood pressure,
diabetes mellitus, antihypertensive drugs, lipid lowerings
betics (n = 92) Non-Diabetics (n = 335) p value
7 ± 84.5 81.3 ± 113.4 0.483
(68.5) 173 (51.6) 0.004
(20.7) 73 (21.8) 0.887
9 ± 8.8 60.2 ± 8.4 0.089
8 ± 3153 3691 ± 3506 0.440
8 ± 5.0 27.9 ± 3.9 <0.001
.4 ± 11.7 96.2 ± 9.9 <0.001
(41.3) 80 (23.9) 0.001
.0 ± 14.7 133.4 ± 17.1 0.067
7 ± 10.1 81.5 ± 11.1 0.169
4 ± 9.2 93.1 ± 9.7 0.783
0 ± 12.1 69.3 ± 10.8 0.005
(82.6) 264 (78.8) 0.468
(65.2) 170 (50.7) 0.018
.5 ± 46.1 87.0 ± 10.1 <0.001
.4 ± 9.5 111.3 ± 17.6 <0.001
± 1.4 5.6 ± 0.3 <0.001
(21.5) 0 (0.0) —
(82.6) 0 (0.0) —
.1 ± 41.1 221.0 ± 36.1 <0.001
.4 ± 35.5 140.1 ± 32.0 <0.001
6 ± 13.0 56.1 ± 14.5 0.009
.0 ± 138.4 124.0 ± 74.8 0.022
8 ± 16.3 80.2 ± 13.0 0.805
(71.7) 297 (88.7) <0.001
(60.9) 102 (30.4) <0.001
68 ± 0.111 0.729 ± 0.089 0.001
(30.4) 47 (14.1) <0.001
(31.5) 48 (14.3) <0.001
42 ± 0.136 0.896 ± 0.109 0.001
absolute frequencies and percentages (%) for categorical data
re, MBP mean blood pressure, FPG fasting plasma glucose, PG postprandial
nsity lipoprotein, IMT intima-media thickness of common carotid artery, TOD
Table 2 Bivariate correlations of markers of dysglycemia with
IMT and other cardiovascular risk factors
FPG (mg/dL) Average PG
(mg/dL)
HbA1c %
Average mean IMT (mm) 0.179** 0.182** 0.191**
Maxima men IMT (mm) 0.173** 0.207** 0.182**
Age (year) 0.058 0.157* 0.019
Body mass index 0.201** 0.081 0.226**







Alcohol drinking (gr/week) −0.064 −0.075 −0.094
METs/hour/week −0.130* −0.109 −0.116
IMT intima-media thickness of common carotid artery, FPG fasting plasma
glucose, PG postprandial glucose, HbA1c glycosylated hemoglobin, HDL high
density lipoprotein, METs metabolic equivalents
P-values by Pearson correlation. *p < 0.05 **p < 0.01
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METs/min/14 days (Model 2). To improve the final inter-
pretation, the C-IMT was multiplied one hundred-fold.
To estimate the odds ratio (OR), two models were con-
structed using the same adjust as the previous multiple
linear regression analyses. The presence of carotid target
organ damage (TOD) was considered to be a variable
dependent and fasting glucose (mg/dL), average postpran-
dial glycemia (mg/dL), HbA1c (%) and altered glucose me-
tabolism were considered to be independent variables.
The data were analyzed using the Statistical Package for
the Social Sciences version 20.0 (SPSS, Chicago, IL, USA).
A value of p < 0.05 was considered statistically significant.
Results
The characteristics of the study subjects, global diabetics
and non-diabetics are shown in Table 1. The mean age
was 60.3 ± 8.5 years, and 55.3 % of the subjects were
women. The mean C-IMT was 0.738 mm (0.768 ± 0.111
in diabetics and 0.729 ± 0.089 in non diabetics).
Among the 335 non-diabetic subjects, 231 had normal
glucose metabolism and 104 prediabetes, the percentage
of subjects depending on the test used in the diagnosis
shown in Fig. 1.
C-IMT shows a positive relationship with fasting glu-
cose, average postprandial glycemia and HbA1c (Table 2).
The 196 patients who have a glucose metabolic alteration
also show mean C-IMT and C-IMT values of 0.039 and
0.044, which are higher than those in subjects without any
glucose metabolic alteration (Additional file 1: Table S1).
Figure 2 and Additional file 1: Table S2 show the
values of the C-IMT organized by tertiles of fasting
glucose (mg/dL), average postprandial glycemia (mg/dL)
and HbA1c.
A multiple linear regression analysis was performed
(Table 3). In model 1, the C-IMT is associated withFig. 1 Percentage of subjects depending on the test used in the
diagnosis of normal glucose metabolism and prediabetes, FPG
fasting plasma glucose. PG postprandial glucose. HbA1c
glycosylated hemoglobindifferent parameters that were used to measure glucose.
After fully adjusting for all parameters (Model 2), C-
IMT maintains a positive association with fasting glu-
cose and with HbA1c. For each 1 % increase in HbA1c,
the C-IMT mean increased 0.016 mm and the C-IMT
maximum increased 0.019 mm. For each 10-mg increase
in fasting plasma glucose, the C-IMT mean and max-
imum increase 0.004 and 0.005 mm, respectively.
The association between IMT average mean and glu-
cose in diabetic subjects and nondiabetic are set out in
the Additional file 1: Table S3.
Table 4 shows the OR of the different markers of gly-
cemia for the presence of carotid TOD. In Model 2, the
association between fasting plasma glucose, postprandial
glucose and HbA1c with the presence of carotid TOD is
maintained (OR = 1.013, OR = 1.010 and OR = 1.425, re-
spectively). Patients who have a glucose metabolic alter-
ation have twice the risk of presenting with a carotid
TOD (OR = 1.920).
The 77 patients who presented with carotid TOD also
presented with fasting glucose levels that were 15.10 mg/ml
higher, average postprandial glycemia that was 18.69 mg/ml
higher and HbA1c that was 0.47 % higher than those with-
out carotid TOD.
Discussion
The results of this study suggest that, in patients with an
intermediate cardiovascular risk, there is a positive associ-
ation between C-IMT and the basal glycemia and HbA1c
levels, which is independent of age, drug treatment and
other confounding factors. The probability of developing
carotid TOD increases with different glycemia parameters.
Similarly, patients who present with a glucose metabolic
alteration have twice the risk of developing TOD.
Fig. 2 ANOVA test results: Carotid intima media thickness by tertiles of fasting plasma glucose (mg/dl), postprandial glucose (mg/dl) and glycated
hemoglobin (%)
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Table 3 Multiple regression analysis with vascular structure as
dependent variable and markers of dysglycemia as independent
variable
Dependent variable: β CI 95 % p value
Average mean IMT Model 1
FPG (mg/dL) 0.046 0.020 to 0.073 0.001
Average PG (mg/dL) 0.035 0.009 to 0.060 0.008
HbA1c (%) 1.658 0.813 to 2.503 <0.001
Average maxima IMT Model 1
FPG (mg/dL) 0.055 0.022 to 0.088 0.001
Average PG (mg/dL) 0.041 0.009 to 0.072 0.012
HbA1c % 1.955 0.908 to 0.302 <0.001
Average mean IMT Model 2
FPG (mg/dL) 0.042 0.002 to 0.082 0.040
Average PG (mg/dL) 0.021 −0.010 to 0.051 0.188
HbA1c (%) 1.589 0.435 to 2.771 0.009
Average maxima IMT Model 2
FPG (mg/dL) 0.052 0.002 to 0.102 0.042
Average PG (mg/dL) 0.024 −0.015 to 0.062 0.225
HbA1c (%) 1.907 0.435 to 3.378 0.011
Dependent variable: IMT: Intima-media thickness of common carotid artery
Indepedent variable: fasting glucose (mg/dL), average postprandial glycemia
(mg/dL) and HbA1c (%)
Adjusted by: Model 1: age and gender
Modelo 2: age, gender, heart rate, smoker, body mass index, no HDL-Cholesterol,
systolic blood pressure, diabetes mellitus, antihypertensive drugs, lipid lowering
drugs, antidiabetic drugs alcohol drinking (gr/week), METs/hour/week
β regression coefficient, CI confidence interval, IMT intima-media thickness of
common carotid artery, FPG fasting plasma glucose, PG postprandial glucose,
HbA1c glycosylated hemoglobin
Table 4 Logistic regression analysis with vascular structure as
dependent variable and markers of dysglycemia as independent
variable
Dependent variable: OR CI 95 % p value
With and without TOD of cartic Modelo 1
FPG (mg/dL) 1.012 1.005 to 1.020 0.001
Average PG (mg/dL) 1.012 1.005 to 1.020 0.001
HbA1c (%) 1.492 1.189 to 1.872 0.001
Altered glucose metabolism 2.153 1.217 to 3.629 0.004
With and without TOD of carotic Modelo 2
FPG (mg/dL) 1.013 1.001 to 1.025 0.039
Average PG (mg/dL) 1.010 1.001 to 1.019 0.010
HbA1c (%) 1.425 1.026 to 1.980 0.034
Altered glucose metabolism* 1.920 1.079 to 3.415 0.026
Dependent variable: target organ damage of carotid
Indepedent variable: fasting glucose (mg/dL), average postprandial glycemia
(mg/dL) and HbA1c (%)
Adjusted by: Model 1: age and gender
Modelo 2: age, gender, heart rate, smoker, body mass index, no HDL-Cholesterol,
systolic blood pressure, diabetes mellitus, antihypertensive drugs, lipid lowering
drugs, antidiabetic drugs alcohol drinking (gr/week), METs/hour/week
OR odds ratio, CI confidence interval, TOD target organ damage, FPG fasting
plasma glucose, PG postprandial glucose, HbA1c glycosylated hemoglobin
TOD = Plaque or carotid IMT >0.90 mm (n = 77)
*Altered glucose metabolism including diabetes and prediabetes subjects
(n = 196)
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HbA1c, the mean C-IMT increases by 0.016 mm and
the maximum C-IMT increases by 0.019. Our results are
consistent with previous studies that were performed in
the Chinese general population [26], and also consistent
with results from the non-diabetic population of a
multi-ethnic atherosclerosis study [11] However, Haring
et al. [27] found a positive association between HbA1c
and mean C-IMT, with a 0.02 mm increase in C-IMT
per 1 % increase in HbA1, but this association did not
remain in the longitudinal analysis.
The association with 2 h postprandial glycemia was
lost after adjusting for confounding factors, and the lo-
gistic regression maintained an OR of 0.010. Previous
publications had different conclusions. For example, 1 h
after glucose overload glycemia was found to be the only
factor associated with C-IMT after adjusting for different
cardiovascular risk factors in a linear regression analysis
[14]. This association was not present 2 h after glucose
overload, but the latter association was found by others
authors [6, 13]. Similarly, in type 2 diabetes patients,
the maximum increase in glycemia is registered within
the first hour after a meal, and this showed a strongercorrelation with C-IMT than with other glycemia
markers such as HbA1C, fasting glucose and glucose
2 h after a meal [28].
A glucose metabolic alteration doubles the risk of de-
veloping carotid TOD. These results are similar to those
of Kurihara et al. [29], who concluded that arterioscler-
otic disease in the coronary artery and the vulnerability
to plaque are more progressed in pre-diabetics and dia-
betics than in non-diabetics. However, the relationship
in pre-diabetic patients is statistically significant after ad-
justment for other cardiovascular risk factors [6].
Other studies that also analyzed the association be-
tween different measurements of glycemia using C-IMT
[1, 13, 30, 31] and found divergent results. In our study,
the independent association of the HbA1C and fasting
glucose with the mean and maximum C-IMT remains
after the adjustment for age, sex, drug treatment and
others cofounding cardiovascular factors, including the as-
sociation between the above-mentioned parameters and
glucose levels 2 h after a meal. These differences could be
explained by the heterogeneity of the studies, different
protocols used to measure C-IMT, different parameters
used to assess glycemia, different ethnicities included in
the studies (for example, Caucasian vs. Asian) and other
features of the subjects such as body mass index or the
prevalence of different cardiovascular risk factors and dif-
ferent variables used to adjust for confounding factors.
These studies suggest that more prospective studies
that analyze the relationship between glycemia and the
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ent ethnicities. Studies that analyze how glycemia at 1
and 2 h after a meal or glucose overload develops, and
its association with C-IMT are required to establish
which postprandial glycemia value is better associated
with subclinical atherosclerotic disease.
Limitations
This study has several limitations that should be consid-
ered in the interpretation of our results. First, because the
study sample comprised exclusively Caucasian adults with
an intermediate cardiovascular, our results may not be
generalizable to other ethnic groups. The observational
study design and the cross-sectional nature of the positive
association between markers of glycemia and C-IMTas an
intermediate risk marker for subclinical atherosclerosis
does not prove causality. Finally, glucose intolerance was
not performed with oral glucose tolerance test with 75 g
of glucose. It was determined with the mean capillary
blood glucose 2 h after breakfast, lunch and dinner. How-
ever, this is the first study to examine the relationship be-
tween the markers of glycemia and vascular structure, as
assessed using the C-IMT, in intermediate-risk cardiovas-
cular patients.
Conclusion
In conclusion, the results of this study suggest that the fast-
ing plasma glucose and the HbA1c levels, but not postpran-
dial glucose, are associated with the mean and maximum
C-IMT. Patients who present the glucose metabolic alter-
ation have more risk of developing carotid TOD compared
with patients with no glucose metabolic alterations.
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